SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the focal point, with traders watching guidance, subscriber engagement, advertising growth, and content strategy amid leadership changes and layoffs. Bearish concerns about competition, content quality, and slowing growth contrast with bullish hopes that low expectations and ad expansion could support a positive reaction.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is drawing attention as traders position around the full Phase 3 melanoma cancer-vaccine data presentation at ESMO, following previously reported positive topline results. Bulls see the readout as validation of the oncology pipeline, while skeptics warn that expectations and valuation are elevated and debate whether the event could prompt profit-taking.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp rebound is drawing attention, with traders attributing the move to possible short covering and technical buying rather than a confirmed new company announcement. The broader debate centers on upcoming DM1 and FSHD siRNA data: Novartis/Aviditys DM1 trial failure raised concerns about whether target knockdown can translate into patient benefit, while some traders argue Sareptas distinct delivery approach and the loss of a competitor could be favorable.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are falling amid concern over plans to list its Monee financial-services arm and launch Sea Cloud, which traders worry could add spending and strategic uncertainty. The community is split between viewing a Monee separation as a potential value unlock and fearing it could weaken the remaining business, while some see the selloff as an overreaction.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces earnings beat and raised outlook drew attention as shares sold off despite strong demand, with traders frustrated by the reaction. The debate centers on whether higher costs, weaker cash generation and an insurance loss outweigh the stronger orders and guidance.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention centers on TG Therapeutics MSToronto presentations, especially initial Phase 1 azer-cel data in progressive MS and additional BRIUMVI results, with commercial growth and a future subcutaneous formulation also part of the bullish case. Traders are anticipating a catalyst-driven move, though some caution that the azer-cel results remain uncertain and complain that the shares have struggled to break out of a trading range.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is selling off despite a third-quarter earnings beat and a new buyback authorization, as traders focus on narrowed full-year profit guidance with an unchanged midpoint and weaker vehicle sales. Some view the drop as overdone given the stronger cash-flow outlook and buyback, while others see the outlook as too cautious to offset the earnings-day disappointment.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

RAP-219s Phase 2 trial in bipolar mania met its primary and secondary endpoints, prompting bullish trading and analyst optimism, including an upgrade. The community is divided over the modest placebo-adjusted benefit and concerns about agitation and discontinuations; the initial surge faded as traders debated whether the data justify further upside.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its prenatal testing business to Labcorp is driving a sharp rally, with traders viewing the cash proceeds as a balance-sheet and strategic boost. Others question the deal because the divested unit contributes revenue, raising concerns about debt and the outlook for the remaining business; some traders are also taking profits after the surge.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Traders are focused on an expected FAA certification announcement for Boeings 737 MAX 10, a long-delayed milestone they see as potentially easing a key overhang. Reactions are divided: some expect the approval to improve sentiment and support future deliveries, while skeptics say it may be priced in and that production execution, delivery pace and cash generation matter more.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders?

Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders? Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 4, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

Are CBZ, SAFT, NEUP Obtaining Fair Deals for their Shareholders?

Are CBZ, SAFT, NEUP Obtaining Fair Deals for their Shareholders? Are CBZ, SAFT, NEUP Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 29, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--UTZ, NEUP, SAFT, and NRIM

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--UTZ, NEUP, SAFT, and NRIM $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--UTZ, NEUP, SAFT, and NRIM PR Newswire NEW YORK, July 29, 2026 NEW YORK, July 29, 2026 /PRNewswire...

NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Neuphoria Therapeutics Inc. (NASDAQ: NEUP) and Scancell Holdings plc. Upon closing of the proposed transaction, Neuphoria shareholders will own 14.5% of the combined company.Halper Sadeh encourages Neuphoria shareholders...

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP) PR Newswire NEW YORK, July 24, 2026 NEW YORK, July 24, 2026...

Scancell Makes Bold U.S. Push with Game-Changing Neuphoria Deal

Scancell Holdings (AIM:SCLP) and Neuphoria Therapeutics (NASDAQ:NEUP) have unveiled a transformative all-share merger designed to position the combined company for its next stage of clinical and commercial growth. Upon closing, the combined business will operate under the Scancell name and intends to list on NASDAQ under the proposed ticker SCLT, while maintaining Scancell's existing AIM listing. The transaction combines Scancell's late-stage immunotherapy pipeline with Neuphoria's public market platform and remaining cash resources, creating a company focused on advancing active cancer immunotherapies with expanded access to U.S. capital markets.

MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership

Equity

Merck cited business reasons for the discontinuation of the investigational drug. 


NEUP Shares Rise Pre-Market As It Explores Strategic Alternatives, Including Potential Acquisition

Neuphoria also added that it received an unsolicited non-binding indication of interest from Lynx1 Master Fund LP earlier this week to acquire all of the outstanding shares of Neuphoria that it does not already own for $5.20 per share in cash. 

Why Did NEUP Stock Surge 64% Today?

Neuphoria Stock Jumps On Triggering $15M Milestone Payment From Merck For Alzheimer's Study: Retail Interest Explodes

This payment represents the second milestone in the collaboration between Neuphoria and Merck, with Neuphoria potentially eligible for up to $450 million in additional milestone payments.


Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded in 1996 and is headquartered in Millis, MA.

Neuphoria Therapeutics Inc.

Neutral Sentiment

<ul class="summary-bullets"><li>The trial tested whether adding MK-1167, a daily capsule, to standard Alzheimer’s medicines could improve memory and thinking.</li><li>Merck ended the trial after an early planned review of the results showed the drug did not perform well enough to continue.</li><li>Merck, however, is still active in Alzheimer’s research.</li></ul>Shares of Merck &amp; Co. Inc. (MRK) fell over 2% on Wednesday after the company terminated a mid-stage study of its Alzheimer’s drug MK-1167 being developed with Neuphoria Therapeutics (NEUP), citing business reasons.The company is no longer looking for participants for the trial intended to evaluate the efficacy and safety of MK-1167 as adjunctive therapy in participants with mild to moderate Alzheimer's disease dementia, according to a post to ClinicalTrials.gov.<a href="https://stocktwits.com/symbol/NEUP">NEUP stock</a> closed the regular trading session down 19% and fell another 3% after hours.&nbsp;<h2 class="st-heading-2">What Happened With The Trial?</h2>The trial tested whether adding MK-1167, a daily capsule, to standard Alzheimer’s medicines could improve memory and thinking.Patients were randomly assigned to receive one of three doses of MK-1167 or a placebo. Neither the patients nor the researchers knew who got the real drug. The main goals were to check for improvements on a common test of thinking skills after 24 weeks and to monitor safety.The study began enrolling people in December 2024 and aimed for about 350 participants across multiple countries. It is now closed, with the last patients finishing in early June 2026.<h2 class="st-heading-2">Why Did Merck Stop It?</h2>Merck ended the trial after an early planned review of the results showed the drug did not perform well enough to continue. The company has stated that no safety concerns were identified during the trial.MK-1167 was designed to help brain cells communicate better by boosting specific signals linked to memory and attention.Merck previously also discontinued the development of another drug being developed with Neuphoria called MK-4334. The drug completed one early-stage study in 2022 that tested its effects on brain signals in healthy volunteers and people with schizophrenia. However, a planned second early-stage study in patients with Alzheimer’s disease who were already taking the drug donepezil was withdrawn before any participants were enrolled. No other compounds from the particular Merck–Neuphoria partnership have entered clinical trials.&nbsp;Merck, however, is still active in Alzheimer’s research. It continues to test another experimental drug, MK-2214, that targets a different protein in the brain. Results from that study are expected in 2029.<h2 class="st-heading-2">How Did MRK Retail Traders React?</h2>On Stocktwits, retail sentiment around MRK stock fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user voiced optimism for MRK stock hitting all-time highs by month-end.<stembedurl>https://www.stocktwits.com/10D_west/message/658049440</stembedurl>According to data from Koyfn, 19 of the 29 analysts covering MRK rate it ‘Buy’ or ‘Strong Buy’ while nine rate it ‘Hold’ and one rates it ‘Strong Sell.’The 12-month average price target on the stock is $130.78, representing a potential upside of over 4% from the stock’s last close.<a href="https://stocktwits.com/symbol/MRK">MRK stock</a> has gained 19% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-up-for-fourth-straight-day-of-gains-before-thursday-deliveries-report-wall-street-expects-year-on-year-growth/cZm3oddR71L">TSLA Stock Up for Fourth Straight Day Before Thursday Deliveries Report — Wall Street Expects Year-On-Year Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Merck logo is displayed on a smartphone screen, with the company's green-themed branding visible in the background, on April 20, 2025, in Chongqing, China. (Photo by Cheng Xin/Getty Images)

Merck cited business reasons for the discontinuation of the investigational drug. 

Merck & Co Inc

Vanguard S&P 500 ETF

Vanguard Total Stock Market ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$3.40
Prev Close	$3.31
Open	$3.37
Dividend Yield	0.00%
50-Day Moving Average	$3.67
Beta	0.79
Avg. Volume	16,405.03
PE Ratio	-0.54

52-Week High	$8.44
52-Week Low	$3.19
Market Capitalization	$17.91M
EPS (Annual)	-$3.06
Price to Book	0.73
Revenue Per Employee	$1.17M

Feed

News

Sentiment

Fundamentals

Info

NEUP Fundamentals